Agenus (AGEN) to Release Earnings on Monday

Key Points

• Agenus is set to release its Q2 2025 earnings on Monday, August 11th, with analysts expecting a loss of ($0.78) per share and revenue of $49.71 million.
• The company's stock traded up to $5.48, with a market capitalization of $150.21 million, and a year range of $1.38 to $7.34.
• Recent analyst upgrades include a boost from HC Wainwright, who raised the rating from "neutral" to "buy" with a target price of $25.00.

Agenus (NASDAQ:AGEN - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.78) per share and revenue of $49.71 million for the quarter.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to the consensus estimate of $26.38 million. On average, analysts expect Agenus to post $-13 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Agenus Price Performance

NASDAQ:AGEN traded up $0.12 during trading hours on Monday, hitting $5.48. The stock had a trading volume of 125,546 shares, compared to its average volume of 844,677. The company has a 50 day simple moving average of $5.26 and a two-hundred day simple moving average of $3.62. Agenus has a one year low of $1.38 and a one year high of $7.34. The firm has a market capitalization of $150.21 million, a price-to-earnings ratio of -0.63 and a beta of 1.62.

Analyst Ratings Changes

A number of research analysts recently commented on the company. HC Wainwright raised Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price on the stock in a research note on Wednesday, June 4th. Wall Street Zen raised Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Robert W. Baird increased their target price on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research note on Wednesday, June 4th. Finally, B. Riley reissued a "buy" rating on shares of Agenus in a research note on Monday, April 21st.

Institutional Trading of Agenus

Several hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new stake in Agenus in the first quarter worth $58,000. AQR Capital Management LLC lifted its stake in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock worth $664,000 after purchasing an additional 427,604 shares during the last quarter. Finally, Invesco Ltd. bought a new stake in Agenus in the first quarter worth $88,000. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.